Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subjects aged 18 to 65 years (inclusive)~* Body mass index (weight \[kg\]/height \[m²\]) ≥30 and ≤45 kg/m² for subjects with uncomplicated obesity, and BMI of ≥27 and ≤45 kg/m² for subjects with obesity with controlled hypertension and/or dyslipidemia~* Normotensive (systolic ≤140 mm Hg and diastolic ≤90 mm Hg). Anti-hypertensive medications were allowed with the exception of alpha-adrenergic blockers and clonidine. Medical regimen was to be stable for at least 6 weeks prior to randomization.~* Medications for the treatment of dyslipidemia were allowed as long as the medical regimen had been stable for at least 6 weeks prior to randomization.~* Free of opioid medication for 7 days prior to randomization~* No clinically significant abnormality of serum albumin, blood urea nitrogen (BUN), creatinine, bilirubin, sodium, potassium, chloride, calcium or phosphorus~* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 times upper limit of normal (ULN)~* No clinically significant abnormality of hematocrit, white blood cell (WBC) count, WBC differential, or platelets~* Fasting glucose \<126 mg/dL and not receiving hypoglycemic agents and fasting triglycerides level \<400 mg/dL~* No clinically significant abnormality on urinalysis~* Thyroid stimulating hormone (TSH) within normal limits or normal triiodothyronine (T3), if TSH was below normal limits~* Female subjects of childbearing potential had a negative serum pregnancy test~* Negative urine drug screen (UDS)~* An IDS-SR score \<2 on individual items: 5 (sadness), 6 (irritability), 7 (anxiety/tension), and 18 (suicidality) and an IDS-SR total score \<30~* Female subjects of childbearing potential were non-lactating and agreed to continue to use effective contraception throughout the study and 30 days after discontinuation of study drug~* Able to comply with all required study procedures and schedule~* Able to speak and read English~* Provided written informed consent~Exclusion Criteria:~* Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome)~* Serious medical condition (including but not limited to renal or hepatic insufficiency; Class III or IV congestive heart failure, history of angina pectoris, myocardial infarction, claudication, or acute limb ischemia within the previous 6 months; lifetime history of stroke)~* History of malignancy within the previous 5 years, with exception of non-melanoma skin cancer or surgically cured cervical cancer~* Lifetime history of serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, or anorexia nervosa~* Current serious psychiatric illness including severe personality disorder (e.g., borderline or antisocial), current severe major depressive disorder, recent (previous 6 months) suicide attempt, current active suicidal ideation or recent hospitalization due to psychiatric illness~* Response to the bipolar disorder questions that indicated the presence of bipolar disorder~* Required medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months prior to randomization~* History of drug or alcohol abuse or dependence (with the exception of nicotine dependence) within 1 year prior to study initiation~* Type I or Type II diabetes mellitus~* Screening ECG with a corrected QT (QTc) interval (using Bazett's formula \>450 millisecond (msec) \[males\] and \>470 msec \[females\]) or the presence of any clinically significant cardiac abnormalities, including but not limited to patterns consistent with myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities~* Received excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer or anticonvulsant agents or agents for the treatment of attention deficit disorder) with the exception of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2 mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any anorectic or weight loss agents; any over the-counter dietary supplements or herbs with psychoactive, appetite or weight effects; alpha-adrenergic blockers; dopamine agonists; clonidine; coumadin; theophylline; cimetidine; oral corticosteroids; cholestyramine; cholestypol; Depo-Provera®; smoking cessation agents; use of opioid or opioid-like analgesics, including analgesics and antitussives~* History of surgical or device (e.g., gastric banding) intervention for obesity~* History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with ≥5 minutes loss of consciousness, concussion symptoms lasting ≥15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures)~* History of treatment with bupropion or naltrexone within the preceding 12 months~* History of hypersensitivity or intolerance to bupropion or naltrexone~* Initiation or discontinuation of tobacco products including inhaled tobacco (e.g., cigarettes, cigars, pipes, etc), chewing tobacco or snuff within 3 months prior to randomization or planned during study participation. Use of nicotine replacement products (e.g., nicotine gum, patch, etc) during study participation was not allowed~* Used drugs, herbs, or dietary supplements believed to significantly affect body weight or participated in a weight loss management program within one month prior to randomization~* Loss or gained \>4.0 kilograms within the previous 3 months prior to randomization~* Females who were pregnant or breast-feeding or planning to become pregnant during the study period or within 30 days of discontinuing study drug~* Planned surgical procedure that could impact the conduct of the study~* Received any investigational drug or used an experimental device or procedure within the previous 30 days~* Participated in any previous clinical trial conducted by Orexigen~* Had any condition that in the opinion of the investigator made the subject unsuitable for inclusion into the study~* Investigators, study personnel, sponsor representatives and their immediate families

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NB32 (Type: EXPERIMENTAL): Naltrexone SR 32 mg/bupropion SR 360 mg/day with ancillary therapy
- Placebo (Type: PLACEBO_COMPARATOR): Placebo with ancillary therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).